Paul A. Volberding, MD Update (Mar-07): It appears that Dr. Volberding has stepped down from the HIV Scientific Advisory Board of The Immune Response Corp. (No word yet on what he will do with his IMNR stock options.) It also appears that it took 3 other HIV/AIDS opinion leaders to replace him. London's Professor Brian Gazzard (Chelsea and Westminster Hospital), Italy's Dr. Mario Clerici (University of Milan) and Spain's Dr. Eduardo Fernandez-Cruz (who at the 2007 CROI presented quite a lame poster on 48 weeks of clinical follow-up with Remune) have joined in his stead. From the October 2006 revisions to the DHHS adult and adolescent HIV treatment guidelines (appendix A): Dr. Volberding serves on the HIV Advisory Boards (and receives compensation) for: Bristol-Myers Squibb Boehringer Ingelheim Gilead Sciences GlaxoSmithKline Merck & Co. Pfizer Dr. Volberding has received honoraria for speaking engagements from: Bristol-Myers Squibb Gilead Sciences GlaxoSmithKline Merck & Co. Ortho Biotech Roche-Trimeris Dr. Volberding serves on the Scientifc Advisory Board (for which he was granted stock options in the company) for: Immune Response Corp. 2004 conflict of interest/competing interest disclosures for Paul A. Volberding Abbott Labs: Consultant Boehringer Ingelheim: HIV Advisory Board, consultant Bristol-Myers Squibb: HIV Advisory Board, speaker, consultant Gilead Sciences: HIV Advisory Board, speaker, consultant GlaxoSmithKline: Speaker, consultant Immune Response: HIV Advisory Board, consultant, stock options Merck: Consultant Ortho Biotech/JNJ: HIV Advisory Board, consultant Pfizer: HIV Advisory Board Source: "Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents," Appendix A, http://www.aidsinfo.nih.gov/guidelines/default_db2.asp?id=50 (accessed March 26, 2005); Yeni PG, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA panel. JAMA. 2004;292:251-265, ); financial disclosures section (p 263) at http://www.iasusa.org/pub/index.html (accessed March 26, 2005). From the IAS treatment guidelines (07/14/2004) Dr Volberding has been a paid consultant for: Abbott Laboratories Boehringer Ingelheim Bristol-Myers Squibb Gilead GlaxoSmithKline Merck Source: see Financial Disclosures section (p 263) of Yeni PG, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA panel. JAMA. 2004;292:251-265. (available for free download (no HTML viewing option) at http://www.iasusa.org/pub/index.html)